A Phase 1 Open-label Pharmacokinetics Study Of Palbociclib, A Cyclin-dependent Kinase 4 And 6 (cdk4/6) Inhibitor, In Postmenopausal Chinese Women With Er (+), Her2 (-) Advanced Breast Cancer

Trial Profile

A Phase 1 Open-label Pharmacokinetics Study Of Palbociclib, A Cyclin-dependent Kinase 4 And 6 (cdk4/6) Inhibitor, In Postmenopausal Chinese Women With Er (+), Her2 (-) Advanced Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 28 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top